Baseline | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |
---|---|---|---|---|---|---|
Group 1 | ||||||
DAS28 | 5.3±1.1 | 4.0±0.5 | 3.7±1.3 | 3.5±1.3 | 3.2±1.2 | 3.0±1.2 |
SDAI | 30.2±12.7 | 16.5±6.1 | 14.9±12.9 | 13.7±11.9 | 11.6±10.2 | 10.4±9.6 |
SJC | 7.2±4.6 | 2.9±3.1 | 2.3±3.8 | 2.0±2.8 | 1.9±3.3 | 1.5±2.4 |
TJC | 9.8±6.4 | 5.5±4.1 | 5.3±6.6 | 5.2±7.0 | 3.6±4.8 | 3.3±4.9 |
HAQ-DI | 1.1±0.7 | 0.8±0.6 | 0.7±0.6 | 0.7±0.6 | 0.6±0.6 | 0.6±0.6 |
ESR (mm/h) | 30.2±29.4 | 18.0±13.3 | 17.2±14.0 | 17.3±15.4 | 16.0±12.9 | 16.1±13.4 |
CRP (mg/L) | 19.4±32.6 | 8.0±8.2 | 7.9±16.4 | 7.6±12.1 | 10.0±21.2 | 7.7±12.0 |
mTSS | 5.5±7.4 | 9.8±9.5 | 13.6±13.2 | 16.1±14.9 | / | / |
Group 2 | ||||||
DAS28 | 4.5±1.3 | 1.7±0.6 | 2.0±1.1 | 1.9±1.0 | 2.0±1.1 | 1.9±0.9 |
SDAI | 23.1±13.9 | 3.0±2.9 | 5.0±6.9 | 4.4±5.1 | 5.4±8.5 | 4.3±5.4 |
SJC | 6.2±5.3 | 0.4±1.1 | 0.4±0.9 | 0.5±1.2 | 1.0±3.6 | 0.4±0.9 |
TJC | 5.6±5.7 | 0.2±0.8 | 0.8±2.2 | 0.8±1.7 | 1.2±3.7 | 0.8±2.2 |
HAQ-DI | 0.8±0.7 | 0.2±0.3 | 0.2±0.4 | 0.2±0.3 | 0.2±0.4 | 0.2±0.4 |
ESR (mm/h) | 25.8±22.4 | 8.9±6.1 | 10.8±9.1 | 10.6±10.2 | 10.6±11.1 | 10.6±10.3 |
CRP (mg/L) | 21.0±42.9 | 4.1±4.7 | 6.1±13.1 | 4.6±7.0 | 4.6±6.5 | 5.3±8.0 |
mTSS | 4.5±6.9 | 6.3±6.9* | 8.2±9.5** | 11.2±11.8*** | / | / |
*p=0.001 versus group 1; **p=0.0005 versus group 1; ***p=0.019 versus group 1.
CRP, C-reactive protein; DAS28, Disease Activity Score in 28 joints; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire-Disability Index; mTSS, van der Heijde modified total Sharp score; SDAI, Simplified Disease Activity Index; SJC, swollen joint count; TJC, tender joint count.